Biotech Business › Vol. 23 Nbr. 3, March 2010
Linked as:Extract
ACH-2684 HAS POTENCY AGAINST HCV AND RESISTANT VARIANTS.
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), New Haven, Conn., has announced the nomination of a lead clinical candidate in its third proprietary program against hepatitis C infection....
See the full content of this document
Sponsored links
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other documents:
IRS Finalizes 403 b Regulations | meetings special medical advisory group, | agency information collection activities proposals submissions and approvals, | Disaster loan areas Iowa, | Sentencia nº 609 de Consiglio di Stato, February 03, 2010 | Sentencia de Cours d appel September 22 2011 caso Cour d appel de Douai 22 septembre ... | Resolución nº 4430 de Corte de Apelaciones de Iquique Sala Primera April 11 2006 | Decisión nº PJ0592011000080 de Tribunal Superior Cuarto de Protección de Niños, Niñas y Adolescentes de Caracas, de November 11, 2011
